DESTINY-Breast03 Phase 3 Study Results

DESTINY-Breast04 Trastuzumab Deruxtecan (T-DXd) vs Treatment of Physician's Choice in Patients with HER2-low Unresectable and/or Metastatic Breast Cancer: Results of DESTINY-Breast04, a Randomized, Phase 3 Study Shanu Modi Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, USA Additional authors: William Jacot, Toshinari Yamashita, Joo Hyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto Ueno, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Xiaojia Wang, Binghe Xu, Dhiraj Gambhire, Lotus Yung, Gerold Meinhardt, Yibin Wang, Nadia Harbeck, David Cameron Daiichi-Sankyo ASCO 2022 #LBA3 Plenary Session On behalf of the investigators 3

View entire presentation